IJAMSVILLE, Md.--(BUSINESS WIRE)--Nov. 19, 2003--Marligen Biosciences Inc. announced today that it has appointed James H. Chamberlain as Chairman of its Board of Directors. Mr. Chamberlain served as Director, President and Chief Executive Officer of BioSource International, Inc. (NASDAQ:BIOI - News), since it was founded in October 1989, and was elected as its Chairman of the Board in November 1993. He retired from all positions in September 2000. Previously, Mr. Chamberlain was Manager of Business Development for Amgen, Inc., where he started and managed the Amgen Biologicals Division. Mr. Chamberlain has held various executive positions with Browning Ferris Industries and Amersham Corporation, a Biomedical Company. He was also a research biochemist for Wm. H. Rorer Pharmaceutical, a major pharmaceutical company. He currently serves as a director of XTRANA Inc, a public Denver based biotechnology firm and has served on the Board of Directors of the West Virginia University Foundation since November 2001. He received his Bachelor of Arts degree from West Virginia University and studied biochemistry at the University of Pittsburgh.
"We consider ourselves very fortunate to have Mr. Chamberlain join us," said Dr, Sherry Challberg, President and Chief Executive Officer of Marligen. "With his extensive experience in the life sciences market, including overall operational issues, financing and corporate governance, we believe he will help us take the Company to the next level as we begin to introduce flagship products based on our exciting new proprietary technologies, and we look forward to working with him in the future."
Mr. Chamberlain said, "I am excited to be working Marligen as it begins to commercialize its proprietary multiplex profiling assays. There is a growing demand for better tools to simultaneously characterize the status of multiple proteins involved in the control of gene expression and the cell cycle. In particular, their novel multiplex transcription factor assays enable comprehensive profiling of the proteins that regulate the expression of all genes, and they are an important target for the development and screening of next generation therapeutics."
The Company anticipates that it will add several other new members to its Board of Directors during the next quarter that will bring additional strength and experience to its management team.
Marligen Biosciences develops, manufactures, and distributes products and technologies used in life science research for analyzing genes and the proteins they encode. Offering molecular biology reagent kits and services through direct sales in the US and through distributors elsewhere, the Company provides products that accelerate healthcare research to the global life sciences research community in over 30 countries worldwide. The Company's next generation products address unmet needs in basic research as well as in drug discovery and development. Products for multiplex profiling of single nucleotide polymorphisms (SNPs), transcription factors and phosphoproteins are in development and are slated for launch next year.
Marligen Biosciences, Inc. Sherry Challberg, Ph.D., 301-874-4990
Source: Marligen Biosciences, Inc.